Theme

Active Pharmaceutical Ingredients - API

CSIR-CDRI’s mission of providing affordable medicines across the globe is duly supported by the persistent efforts of a team of about 100 dedicated and talented scientists, technical officers and research scholars.

CSIR-CDRI houses state-of-the-art research facilities for its API process development at Lucknow, India with dedicated team working on synthetic organic chemistry, process engineering and analytical development.

• Transferred more than 130 indigenous technologies to the pharmaceutical companies.
• The product development is achieved through excellent route design keeping the scalability, green principles, robustness and cost-effectiveness in mind.
• Our analytical facilities are well equipped with high-end instruments like NMR, Mass, LC-MS-MS, GC-MS, single crystal XRD etc.
• Currently focussing on Novel Process Research For Blockbuster Drugs like

Treprostinil {Pulmonary Arterial Hypertension, Prostaglandin I2 receptor agonists}

Sorafenib {Multi Targeted Kinase Inhibitor}

Empagliflozin {Sodium Glucose Co-transporter 2 Inhibitor for Type 2 Diabetes}

Sunitinib {Tyrosine Kinase Inhibitor in Renal Cell carcinoma}

Bedaquiline {Mycobacterium Tuberculosis ATP Synthase Inhibitor}

• With a committed team consisting of experienced synthetic organic chemists, our capabilities are limitless-from development of a simple achiral molecule to highly complex molecule with multiple chiral centres.